Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TNNC1 | P63316 | 4/20 | 0.40 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7251279 | 0.91 | PARP10 (0.58) | PARP10S1PR1CA1CA2PARP1 | |
| SCHEMBL11120189 | 0.85 | ALDH1A1 (0.52) | EPHX2NR1H4S1PR1 | |
| Hydrochloric Acid SCHEMBL11189806 | 0.84 | ALDH1A1 (0.50) | EPHX2NR1H4S1PR1 | |
| SCHEMBL11125011 | 0.84 | S1PR1 (0.43) | S1PR1TNNC1SGPL1S1PR4GPR183 | |
| SCHEMBL21058265 | 0.82 | SLC6A2 (0.44) | S1PR1TNNC1SGPL1S1PR4GPR183 | |
| SCHEMBL10965456 | 0.81 | LOXL2 (0.59) | CA1CA2 | |
| SCHEMBL11137810 | 0.81 | PLK1 (0.62) | EPHX2NR1H4CA1CA2 | |
| SCHEMBL11207384 | 0.81 | HDAC1 (0.57) | — | |
| SCHEMBL11141055 | 0.81 | NR1H4 (0.49) | EPHX2NR1H4S1PR1MAOB | |
| SCHEMBL12121048 | 0.80 | EPHX2 (0.43) | EPHX2NR1H4PLA2G10PLA2G2APARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0047536-B1 | SUBSTITUTED PROPYLAMINES | ELI LILLY AND COMPANY (US) | 1984-06-27 | — | — | EP | claimed |
| US-7041684-B2 | Selective β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050043337-A1 | Selective beta3 adrenergic agonists | RITO CHRISTOPHER J (US) | 2005-02-24 | — | — | US | disclosed |
| US-6686372-B2 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-6617347-B1 | Substituted pyrazoles are treatment of Type II diabetes and obesity. | ELI LILLY AND COMPANY | 2003-09-09 | — | — | US | disclosed |
| US-20020165234-A1 | Selective B3 adrenergic agonists | CROWELL THOMAS A (US) | 2002-11-07 | — | — | US | disclosed |
| US-6413991-B1 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2002-07-02 | — | — | US | disclosed |
| EP-0827746-B1 | Carbazole analogues as selective beta3 adrenergic agonists | LILLY CO ELI (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6140352-A | FOR AGONIZING THE BETA 3 ADRENERGIC RECEPTOR TO TREAT TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| US-6046227-A | USEFUL IN THE TREATMENT OF TYPE II DIABETES AND OBESITY; A SUBSTITUTED PYRAZINE COMPOUND | ELI LILLY AND COMPANY (US) | 2000-04-04 | — | — | US | disclosed |
| US-4849453-A | ANIMAL GROWTH REGULATORS | ELI LILLY AND COMPANY (US) | 1989-07-18 | — | — | US | disclosed |
| US-4734437-A | PHENETHANOLAMINES | ELI LILLY AND COMPANY (US) | 1988-03-29 | — | — | US | disclosed |
| EP-0241618-A2 | Phenyl ethanol amine derivative for use as an oncolytic medicament | ELI LILLY AND COMPANY (US) | 1987-10-21 | — | — | EP | disclosed |
| US-4690951-A | B-PHENETHANGLAMINES; FEED EFFICIENCY AND LEANESS | ELI LILLY AND COMPANY (US) | 1987-09-01 | — | — | US | disclosed |
| EP-0117647-A1 | Improvements in or relating to phenethanolamines | ELI LILLY AND COMPANY (US) | 1984-09-05 | — | — | EP | disclosed |
| EP-0047536-B1 | SUBSTITUTED PROPYLAMINES | ELI LILLY AND COMPANY (US) | 1984-06-27 | — | — | EP | disclosed |
| EP-0007206-B1 | PHENETHANOLAMINES, THEIR FORMULATIONS, PREPARATION AND USE | ELI LILLY AND COMPANY (US) | 1983-02-23 | — | — | EP | disclosed |
| EP-0047536-A2 | Substituted propylamines | ELI LILLY AND COMPANY (US) | 1982-03-17 | — | — | EP | disclosed |
| EP-0047536-A2 | Substituted propylamines | ELI LILLY AND COMPANY (US) | 1982-03-17 | — | — | EP | disclosed |
| EP-0007206-A1 | Phenethanolamines, their formulations, preparation and use | ELI LILLY AND COMPANY (US) | 1980-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043337-A1 | Selective beta3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | EPHX2 1061/4885NR1H4 90/4885PLA2G10 3450/4885 |
| US-20020165234-A1 | Selective B3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | EPHX2 799/4885NR1H4 46/4885PLA2G10 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.